Aerovate Therapeutics Valuation
| AVTE Stock | USD 2.58 0.15 6.17% |
Based on Macroaxis valuation methodology, the firm appears to be fairly valued. Aerovate Therapeutics shows a prevailing Real Value of $2.56 per share. The current price of the firm is $2.58. Our model approximates the value of Aerovate Therapeutics from analyzing the firm fundamentals such as Current Valuation of (13.6 M), return on equity of -0.82, and Shares Owned By Insiders of 0.01 % as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Aerovate Therapeutics' valuation include:
Fairly Valued
Today
Please note that Aerovate Therapeutics' price fluctuation is risky at this time. Calculation of the real value of Aerovate Therapeutics is based on 3 months time horizon. Increasing Aerovate Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Aerovate stock is determined by what a typical buyer is willing to pay for full or partial control of Aerovate Therapeutics. Since Aerovate Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Aerovate Stock. However, Aerovate Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 2.58 | Real 2.56 | Target 2.33 | Hype 2.59 |
The real value of Aerovate Stock, also known as its intrinsic value, is the underlying worth of Aerovate Therapeutics Company, which is reflected in its stock price. It is based on Aerovate Therapeutics' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Aerovate Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Aerovate Therapeutics helps investors to forecast how Aerovate stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Aerovate Therapeutics more accurately as focusing exclusively on Aerovate Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Aerovate Therapeutics' intrinsic value based on its ongoing forecasts of Aerovate Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Aerovate Therapeutics' closest peers. If more than one evaluation category is relevant for Aerovate Therapeutics we suggest using both methods to arrive at a better estimate.
Aerovate Therapeutics Cash |
|
Aerovate Valuation Trend
Comparing Aerovate Therapeutics' enterprise value against its market capitalization is a good way to estimate the value of Aerovate Therapeutics uage its performance over time. This information may sometimes be enough for investors to make reasonable market timing decisions.
Aerovate Therapeutics Total Value Analysis
Aerovate Therapeutics is presently anticipated to have valuation of (13.6 M) with market capitalization of 74.59 M, debt of 675 K, and cash on hands of 151.99 M. The negative valuation of Aerovate Therapeutics may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the Aerovate Therapeutics fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(13.6 M) | 74.59 M | 675 K | 151.99 M |
Aerovate Therapeutics Asset Utilization
One of the ways to look at asset utilization of Aerovate is to check how much profit was generated for every dollar of assets it reports. Aerovate Therapeutics shows a negative utilization of assets of -0.49 percent, losing $0.004867 for each dollar of assets held by the firm. Inadequate asset utilization signifies that the company is being less effective with each dollar of assets it shows. Put another way, asset utilization of Aerovate Therapeutics shows how discouraging it operates for each dollar spent on its assets.Aerovate Therapeutics Ownership Allocation
The majority of Aerovate Therapeutics outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Aerovate Therapeutics to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Aerovate Therapeutics. Please pay attention to any change in the institutional holdings of Aerovate Therapeutics as this could imply that something significant has changed or is about to change at the company.Aerovate Therapeutics Profitability Analysis
Net Loss for the year was (75.52 M) with profit before overhead, payroll, taxes, and interest of 0.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Aerovate Therapeutics' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Aerovate Therapeutics and how it compares across the competition.
About Aerovate Therapeutics Valuation
The stock valuation mechanism determines Aerovate Therapeutics' current worth on a weekly basis. Our valuation model uses a comparative analysis of Aerovate Therapeutics. We calculate exposure to Aerovate Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Aerovate Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -86.4 K | -82.1 K |
Aerovate Therapeutics Growth Indicators
Investing in growth stocks can be very risky. If the company such as Aerovate Therapeutics does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 26.3 M |
Aerovate Therapeutics Current Valuation Indicators
Valuation refers to the process of determining the present value of Aerovate Therapeutics and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Aerovate we look at many different elements of the entity such as Aerovate's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Aerovate Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Aerovate Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Aerovate Therapeutics' worth.Complementary Tools for Aerovate Stock analysis
When running Aerovate Therapeutics' price analysis, check to measure Aerovate Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aerovate Therapeutics is operating at the current time. Most of Aerovate Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aerovate Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aerovate Therapeutics' price. Additionally, you may evaluate how the addition of Aerovate Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal |